Considering that these trials used careful screening to avoid treating patients with any additional cardiovascular risk factors, this may mean that AMPH treatment is likely to be unsafe in the broader population of stroke patients (Martinsson et al., 2007; Sprigg and Bath, 2009; Engelter et al., 2010). This evidence concerns the gene AMPH and stroke disorder.